View our current portfolio across the UK and Ireland
Below is a list of the LEO Pharma products for the UK and Ireland, with an external link to their Summary of Product Characteristics (SmPC) and where you can also find the Patient Information Leaflets (PIL).
Please note that this information is not intended to replace the advice of a qualified Healthcare Professional.
United Kingdom
Dermatology
Adtralza®▼300 mg solution for injection in pre-filled pen
(tralokinumab)
Adtralza®▼150 mg solution for injection in pre-filled syringe
(tralokinumab)
Dovobet® gel
(calcipotriol + betamethasone dipropionate)Dovobet® ointment
(calcipotriol + betamethasone dipropionate)
Dovonex® ointment
(calcipotriol)
Enstilar® cutaneous foam
(calcipotriol + betamethasone dipropionate)
Finacea® gel
(azelaic acid)
Fucibet® cream
(fusidic acid + betamethasone valerate)
Fucidin® cream
(fusidic acid)
Fucidin® H cream
(fusidic acid + hydrocortisone acetate)
Fucidin® ointment
(sodium fusidate)
Fucidin® Oral suspension
(fusidic acid)
Fucidin® tablets
(sodium fusidate)
Kyntheum® 210 mg Solution for injection
(brodalumab)
Protopic® 0.03% ointment
(tacrolimus)
Protopic® 0.1% ointment
(tacrolimus)
Skinoren® cream
(azelaic acid)
Heparin injection BP 1,000 IU
Heparin injection BP 5,000 IU
innohep®/tinzaparin sodium vial 10,000 IU/ml
innohep®/tinzaparin sodium vial 20,000 IU/ml
innohep®/tinzaparin sodium syringe 10,000 IU/ml
innohep®/tinzaparin sodium syringe 20,000 IU/ml
Adtralza®▼300 mg solution for injection in pre-filled pen
(tralokinumab)
Adtralza®▼150 mg solution for injection in pre-filled syringe
(tralokinumab)
Dovobet® gel
(calcipotriol + betamethasone dipropionate)
Dovonex® cream
(calcipotriol)
Dovonex® ointment
(calcipotriol)
Enstilar® cutaneous foam
(calcipotriol+ betamethasone dipropionate)
Fucibet® cream
(fusidic acid + betamethasone valerate)
Fucibet® lipid cream
(fusidic acid + betamethasone valerate)
Fucidin® H cream
(fusidic acid + hydrocortisone acetate)
Fucidin® cream
(fusidic acid)
Fucidin® ointment
(sodium fusidate)
Fucidin® tablets
(sodium fusidate)
Kyntheum® 210 mg Solution for injection
(brodalumab)
Protopic® 0.03% ointment
(tacrolimus)
Protopic® 0.1% ointment
(tacrolimus)
Skinoren® gel
(azelaic acid)
Travocort
(diflucortolone valerate + Isoconazole nitrate)
innohep® vial 10,000 IU/ml
(tinzaparin sodium)
innohep® vial 20,000 IU/ml
(tinzaparin sodium)
innohep® syringe 2,500 IU/ml
(tinzaparin sodium)
innohep® syringe 3,500 IU/ml
(tinzaparin sodium)
innohep® syringe 4,500 IU/ml
(tinzaparin sodium)
innohep® syringe 8,000 IU/ 0.4 ml
(tinzaparin sodium)
innohep® syringe 10,000 IU/0.5 ml
(tinzaparin sodium)
innohep® syringe 12,000 IU/0.6 ml
(tinzaparin sodium)
innohep® syringe 14,000 IU/0.7 ml
(tinzaparin sodium)
innohep® syringe 16,000 IU/0.8 ml
(tinzaparin sodium)
innohep® syringe 18,000 IU/0.9 ml
(tinzaparin sodium)
Protamine Sulphate LEO Pharma 1400 anti-heparin IU/ml
Read more about LEO Pharma UK/Ireland in thrombosis.
▼These medicines are subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See https://yellowcard.mhra.gov.uk/ for how to report side effects. Healthcare professionals and patients are asked to report any suspected adverse reactions.
Report any side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet.
To report a side effect about a LEO Pharma product from within the UK and Ireland, please use our online report form.
If you wish to report a side effect via email, please address it to ukdrug.safety@leo-pharma.com. Alternatively, if you would like to speak with our Medical Information team you can call +44 (0) 1844 347 333, pressing '2' for Medical Information (UK) or +353 1 4908924 (Ireland).
You can also report side effects directly via the national reporting systems:
- For the United Kingdom, via the Yellow Card Scheme, visit www.mhra.gov.uk/yellowcard, or search MHRA Yellow Card in the Google Play or Apple App Store
- For Ireland, via HPRA Pharmacovigilance, please email medsafety@hpra.ie
By reporting side effects, you can help provide more information on the safety of this medicine.
LEO Pharma UK and Ireland are required to record all relevant data to ensure the safety of our products. You can find more information about which data we record, your rights and how data privacy is ensured etc. here. If you have any questions, please contact us via email at medical-info.uk@leo-pharma.com or by telephone on +44 (0) 1844 347 333, pressing '2' for Medical Information. For LEO Pharma IE, contact +353 1 4908924.
MAT-76739 October 2024
